Talphera (NASDAQ:TLPH – Get Free Report) will likely be posting its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Talphera to announce earnings of ($0.06) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
Talphera (NASDAQ:TLPH – Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.06) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.06). On average, analysts expect Talphera to post ($0.23) EPS for the current fiscal year and ($0.27) EPS for the next fiscal year.
Talphera Trading Up 3.8%
Shares of TLPH opened at $1.05 on Wednesday. The stock has a market capitalization of $54.40 million, a P/E ratio of -3.85 and a beta of 0.77. Talphera has a 12 month low of $0.69 and a 12 month high of $1.57. The firm’s fifty day simple moving average is $1.14 and its two-hundred day simple moving average is $1.01.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Talphera in a research report on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Talphera in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Talphera has a consensus rating of “Hold” and a consensus price target of $3.00.
Check Out Our Latest Stock Report on Talphera
About Talphera
Talphera, formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing therapies for acute pain. The company’s lead product is DSUVIA, a sublingual tablet containing sufentanil, an opioid analgesic designed to provide rapid relief for adults experiencing acute pain severe enough to require an opioid.
DSUVIA is intended for use in medically supervised settings, including hospitals, surgical centers and other certified health-care environments.
Featured Stories
- Five stocks we like better than Talphera
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
